Last updated on June 2018

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)


Brief description of study

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Clinical Study Identifier: NCT02576574

Contact Investigators or Research Sites near you

Start Over

Maritha Rossouw

Johese Clinical Research
Pretoria, South Africa
7.12miles
  Connect »

Lydia Dreosti

University of Pretoria Oncology Department
Pretoria, South Africa
9.96miles
  Connect »